Transcend Medical is focused on the development of medical devices for the treatment of glaucoma, the leading cause of adult irreversible blindness. It is estimated that nearly four million people in the US and over 60 million worldwide are afflicted with the disease today and the numbers are expected to grow to nearly six million in the US, and to over 70 million worldwide by the year 2015.
In 2005, Transcend Medical was the first company to spin out of ForSight Labs, an incubator solely focused on ophthalmic innovations. Transcend Medical was granted CE mark for the CyPass Micro-Stent® in 2008, and is being evaluated in several clinical studies in the US and abroad, including the COMPASS multi-center clinical trial.
Funding Rounds (5) - $87.2MUpdate
Current Team (6)Update
Board Members and Advisors (4)Update
|Feb 19, 2016||europeanpharmaceuticalreview.com - Eye care company Alcon acquires Transcend Medical|
|Dec 22, 2015||PRNewswire All - Global Glaucoma Surgical Devices Market 2016-2020 - Leading Vendors are Alcon, Abbott Medical Optics, Carl Zeiss Meditec & Ellex Medical|
|Dec 22, 2015||PRNewswire UK All - Global Glaucoma Surgical Devices Market 2016-2020 - Leading Vendors are Alcon, Abbott Medical Optics, Carl Zeiss Meditec & Ellex Medical|
|Dec 21, 2015||PRNewswire All - Global Glaucoma Surgical Devices Market 2016-2020|
|Oct 30, 2015||SoCal - Tech - Glaukos Settles Patent Suit|
|Oct 30, 2015||Market Wired - Top - Transcend Medical and Glaukos Corporation Settle Patent Litigation|
|Oct 29, 2015||Business Wire - Glaukos Announces Settlement of Patent Litigation with Transcend Medical|
|Oct 22, 2015||Market Wired - Top - Transcend Medical Submits Final Module of FDA Premarket Approval Application for the CyPass® Glaucoma Micro-Stent|
Transcend Medical, Inc.™
127 Independence Drive
Menlo Park, CA 94025